Results 201 to 210 of about 2,767,698 (346)
Pre‐Diagnostic Features of Multiple Sclerosis in a Diverse UK Cohort: A Nested Case–Control Study
ABSTRACT Background Many patients with Multiple Sclerosis (MS) experience nonspecific symptoms prior to diagnosis. This period—the 'MS prodrome'—has been described in socio‐economically homogeneous cohorts to date. It remains unclear to what extent events prior to an MS diagnosis differ according to social determinants of health. Methods We conducted a
Pooja Tank +3 more
wiley +1 more source
Impact of Particle Size on the Aerobic Decomposition and Fertilizer Efficiency of Corn Cobs: A Sustainable Waste-to-Resource Approach. [PDF]
Liu Q +9 more
europepmc +1 more source
Inert dark matter and strong electroweak phase transition [PDF]
Grzegorz Gil +2 more
openalex +1 more source
Longitudinal changes in salivary biomarkers in Parkinson’s disease (PD) from early (T0) to 4‐year follow‐up (T1), quantified by ELISA: oligomeric and total α‐synuclein, total and phosphorylated tau, MAP1LC3B (autophagy), and TNFa (inflammation). Blue arrows indicate direction of change at T1 vs T0 (up = increase; down = decrease).
Maria Ilenia De Bartolo +13 more
wiley +1 more source
The Potential of β-Synuclein-Specific Regulatory T Cell Therapy as a Treatment for Progressive Multiple Sclerosis. [PDF]
Osmond GE, John NA, Ting YT, Ooi JD.
europepmc +1 more source
Liquid–gas phase transition of supernova matter and its relation to nucleosynthesis [PDF]
C Ishizuka +5 more
openalex +1 more source
Tracking Motor Progression and Device‐Aided Therapy Eligibility in Parkinson's Disease
ABSTRACT Objective To characterise the progression of motor symptoms and identify eligibility for device‐aided therapies in Parkinson's disease, using both the 5‐2‐1 criteria and a refined clinical definition, while examining differences across genetic subgroups.
David Ledingham +7 more
wiley +1 more source
Explainable AI-driven precision clinical trial enrichment: demonstration of the NetraAI platform with a phase II depression trial. [PDF]
Geraci J +8 more
europepmc +1 more source

